Canadian Ticagrelor Survey

Completed

• Conditions: Acute Coronary Syndrome

• Registration Number: NCT01757483
• Lead Sponsor: AstraZeneca

Brief Summary

This study is designed to evaluate the effectiveness of the current ticagrelor risk minimisation strategy in Canada through a prescriber knowledge and understanding (KAU) survey of selected important identified safety concerns (i.e., bleeding, dyspnea and drug interactions) and ASA dosage.

Detailed Description

Effectiveness of risk minimisation interventions for ticagrelor in Canada

Study Timeline

• Study Start: 2012-11
• Study First Submitted: 2012-12-18
• Study First Submitted QC: 2012-12-21
• Study First Posted: 2012-12-31
• Primary Completion: 2014-12
• Study Completion: 2014-12
• Status Verified: 2015-12
• Last Update Submitted: 2015-12-08
• Last Update Posted: 2015-12-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 244

Inclusion Criteria

• N/A (All prescribers will be contacted for participation)

Exclusion Criteria

• Participation in a previous wave of the survey.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
KAU Questionnaire: Knowledge of the 4 key safety issues pertaining to ticagrelor (adequate or inadequate for each safety issue)	2 months

Secondary Outcome Measures

Name	Time	Method
KAU Questionnaire: Practice characteristics	2 months
KAU Questionnaire: The difference in knowledge of understanding across the key safety concerns	2 months
KAU Questionnaire: Association between prescribers' characteristics and knowledge and understanding of the key safety concerns.	2 months

Trial Locations

Locations (1)

Research Site; 🇨🇦 Montreal, Quebec, Canada